Literature DB >> 33375932

Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.

T Vanassche1,2, M M Engelen3,4, Q Van Thillo5, J Wauters6, J Gunst7, C Wouters8,9, C Vandenbriele3,4, S Rex4,10, L Liesenborghs3,11, A Wilmer6, P Meersseman6, G Van den Berghe7, D Dauwe7, G Verbeke12, M Thomeer13,14, T Fivez14,15, D Mesotten14,15, D Ruttens13, L Heytens16, I Dapper17, S Tuyls18, B De Tavernier17, P Verhamme3,4.   

Abstract

Entities:  

Year:  2020        PMID： 33375932      PMCID： PMC7770739          DOI： 10.1186/s13063-020-04991-y

Source DB:  PubMed          Journal:  Trials        ISSN： 1745-6215            Impact factor:   2.279


× No keyword cloud information.
  1 in total

1.  A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.

Authors:  T Vanassche; M M Engelen; Q Van Thillo; J Wauters; J Gunst; C Wouters; C Vandenbriele; S Rex; L Liesenborghs; A Wilmer; P Meersseman; G Van den Berghe; D Dauwe; G Verbeke; M Thomeer; T Fivez; D Mesotten; D Ruttens; L Heytens; I Dapper; S Tuyls; B De Tavernier; P Verhamme
Journal:  Trials       Date:  2020-12-09       Impact factor: 2.728
  1 in total
  1 in total

Review 1.  Anticoagulants for people hospitalised with COVID-19.

Authors:  Ronald Lg Flumignan; Vinicius T Civile; Jéssica Dantas de Sá Tinôco; Patricia If Pascoal; Libnah L Areias; Charbel F Matar; Britta Tendal; Virginia Fm Trevisani; Álvaro N Atallah; Luis Cu Nakano
Journal:  Cochrane Database Syst Rev       Date:  2022-03-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.